The sustained delivery system of the antiinfection peptide LL37 system — a potentially new treatment method of ocular infections. Report 1. Testing of different nano- and microparticles as carriers of LL37
DOI:
https://doi.org/10.31288/oftalmolzh201421721Keywords:
Ocular infection, LL37, antiinfection peptide sustained delivery systemAbstract
Purpose. To develop anti-infective peptide (AIP) LL37sustained delivery system that can be used for ocular infections treatment.
Methods. AIPLL37(cathelicidin) was encapsulated in different particles (alginate, chitosan, silica) under magnetic stirring. Encapsulation efficacy (EE) and LL37 release from particles was checked using the ELISA method. The particle morphology was studied by transmission electron or light microscopy. Cytotoxicity of particles with encapsulated LL37was assessed using WST-1 based colorimetric assay.
Results. EE of LL37in the alginate microparticles (AMPs) was 13.8 %. AMP size was 15—20 um. EE of LL37in silica nanoparticles (SiNPs) was 54.4 %. SNPsize was 10—20 nm. Sustained release of LL37in AMPs occurred up to the 7th day and in SNP's — up to the 21st day. No LL37 release occurred from chitosan particles. WST-1 based colorimetric assay showed no increased cytotoxicity regarding human corneal epithelial cells of particles with encapsulated LL37compared to control clear particles.
Conclusion. For the first time micro - and nanoparticle based AIP LL37 sustaineddelivery system was developed. Sustained release of LL37 from AMPs and SiNPs was proved. No cell toxicity was found. SiNP encapsulated LL37showed better EE and longer release of AIP compared to AMP encapsulated LL37.
References
1.Bareiss B, Ghorbani M, Li F, et al. Controlled release of acyclovir through bioengineered corneal implants with silica nanoparticle carriers. Open Tissue Eng. Regen. Med. J. 2010;3:10-7.https://doi.org/10.2174/1875043501003010010
2.Barlow PG, Svoboda P, Mackellar A, et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS ONE. 2011;6(10):e25333.https://doi.org/10.1371/journal.pone.0025333
3.Bertino JS Jr. Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics. Clin. Ophthalmol. 2009;3:507-21.https://doi.org/10.2147/OPTH.S5778
4.Brogden K. A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nature Rev. Microbiol. 2005;3:238-50.https://doi.org/10.1038/nrmicro1098
5.Chetoni P, Rossi S, Burgalassi S et al. Comparison of li-posome-encapsulated acyclovir with acyclovir ointment: ocular pharmacokinetics in rabbits. J. Ocul. Pharmacol. Ther. 2004;20(2):169-77.https://doi.org/10.1089/108076804773710849
6.Donadio S, Maffioli S, Monciardini P, Sosio M, Jabes D. Antibiotic discovery in the twenty-first century: Current trends and future perspectives. J. Antibiot. (Tokyo). 2010; 63(8):423-30.https://doi.org/10.1038/ja.2010.62
7.Fresta M, Fontana G, Bucolo C et al. Ocular tolerability and in vivo bioavailability of poly (ethyleneglycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulat-ed acyclovir. J. Pharm. Sci. 2001;90(3):288- 97.https://doi.org/10.1002/1520-6017(200103)90:3<288::AID-JPS4>3.0.CO;2-5
8.Gordon YJ, Huang LC, Romanowski EG et al. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr. Eye Res. 2005; 30(5):385- 94.
https://doi.org/10.1080/02713680590934111
9.Izquierdo-Barba I, Vallet-RegH M, Kupferschmidt N, et al. Incorporation of antimicrobial compounds in mesoporous silica film monolith. Biomaterials. 2009; 30(29):5729-36.https://doi.org/10.1016/j.biomaterials.2009.07.003
10.Newman H, Gooding C. Viral ocular manifestations: a broad overview. Rev. Med. Virol. 2013;23(5):281- 94.https://doi.org/10.1002/rmv.1749
11.Ramos R, Domingues L, Gama M. LL37, a human antimicrobial peptide with immunomodulatory properties. Science against microbial pathogens: communicating current research and technological advances: Microbiology Book Series [edit. A. Mnndez-Vilas]. Badajoz : Formatex Research Center. 2011;2:915-25.
12.Steinstraesser L, Tippler B, Mertens J et al. Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirology. 2005;2:2.https://doi.org/10.1186/1742-4690-2-2
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 О. І. Бузник
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
